Shares of Epizyme Inc (NASDAQ:EPZM) have been given an average rating of “Buy” by the fifteen research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $23.00.
Several equities analysts have issued reports on the company. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, January 6th. ValuEngine upgraded Epizyme from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Roth Capital assumed coverage on Epizyme in a research report on Thursday, February 1st. They set a “buy” rating and a $24.00 target price on the stock. Oppenheimer set a $26.00 target price on Epizyme and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Finally, Cann reiterated a “buy” rating and set a $26.00 target price on shares of Epizyme in a research report on Thursday, November 2nd.
In related news, COO Matthew Ros sold 72,264 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the sale, the chief operating officer now owns 74,867 shares in the company, valued at approximately $1,245,038.21. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 25.20% of the company’s stock.
Shares of Epizyme (NASDAQ EPZM) traded down $0.50 during mid-day trading on Wednesday, reaching $18.15. The company had a trading volume of 300,800 shares, compared to its average volume of 488,506. The firm has a market cap of $1,260.00, a PE ratio of -8.00 and a beta of 2.19. Epizyme has a 1 year low of $9.30 and a 1 year high of $20.45.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://weekherald.com/2018/03/14/epizyme-inc-epzm-receives-consensus-recommendation-of-buy-from-analysts.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.